People spotlight — August 2021

Pfizer announced that Aamir Malik has joined the company as executive vice president and chief business innovation officer. Malik will be a member of Pfizer’s executive leadership team reporting to chairman and CEO Albert Bourla. He joins Pfizer from McKinsey & Company, where he most recently served as the managing partner responsible for the firm’s US operations.

Johnson & Johnson revealed that Alex Gorsky, currently chairman and CEO, will serve as executive chairman of J&J and transition the CEO role to Joaquin Duato, currently vice chairman of the company’s executive committee, effective Jan. 3, 2022. Following the transition of the CEO role, Duato will also be appointed as a member of J&J's board of directors.

Truveris, a digital health company focused on prescription drug affordability, has named Nanette Oddo president and CEO. Oddo previously served as Truveris’ chief strategy officer.

Nanette Oddo. Credit: Truveris

Novavax, Inc, a biotech company that develops vaccines for serious infectious diseases, has appointed Jim Kelly as executive vice president, CFO and treasurer, and Nasir Egal, PhD, as senior vice president, quality assurance. Kelly, who brings more than 25 years of industry experience in commercial and clinical-stage companies to Novavax, will report to Stanley C. Erck, president and CEO, while Dr. Egal, who most recently served as the head of global quality external affairs at Sanofi, will report to Rick Crowley, executive vice president and COO.

Solid Biosciences Inc., which focuses on advancing therapies for Duchenne muscular dystrophy, announced that Michael Inbar, CPA, MBA, has joined the company as senior vice president, finance, effective since Aug. 16. He brings to Solid an extensive background in public accounting, with expertise in building finance teams, designing financial processes and implementing new systems.

Timothy Compton. Credit: Alcami

The board of directors at Alcami Corp., a global pharmaceutical contract development and manufacturing organization (CDMO), has appointed Timothy Compton as chief business officer. Compton, with 25-plus years of industry experience leading business teams, will be responsible for driving the growth of Alcami's service offerings.

Otonomy, Inc., a biopharma company that develops novel therapeutics for neurotology, appointed Jill Broadfoot to its board of directors. Since 2018, Broadfoot has served as CFO of aTyr Pharma, Inc. Before joining aTyr, she served as CFO of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the US-based pharmaceutical and bioceuticals entities.

Altasciences, a mid-size contract research organization that provides pharma and biotech companies with an approach to formulation, manufacturing and analytical services, appointed Bruce Frank, PhD, as vice president, CDMO operations. Dr. Frank has 30 years of experience with product formulation and development, leading discovery chemistry, new technology evaluation, and project management initiatives, in both small and large biotech firms.